Nilogen Oncosystems

We’re excited to continue sharing our innovations at SITC 2024! On 9th November 2024, join us to explore our cutting-edge research: 🔬 Advancing Cancer Therapy: High-Content Imaging for Precise Tumor Cell Killing Analysis in Patient-Derived Tumoroids Uncover how high-content imaging is enhancing our understanding of tumor cell killing with patient-derived tumoroids. 🔬 Enhancing T Cell Persistence in Adoptive Cell Therapy: Leveraging Tumoroid-Based ex-vivo Assays See how our tumoroid-based ex-vivo assays are improving preclinical evaluation of T cell persistence in adoptive cell therapies. 🔬 Assessing Immunotherapy Efficacy with the 3D-EXplore Platform: Focus on PD-1/PD-L1 Inhibitors in NSCLC Discover insights into the effectiveness of PD-1/PD-L1 inhibitors using Nilogen Oncosystems’ 3D-EXplore Platform for NSCLC tumors. 🔬 Predictive Modeling of Immune-Related Adverse Events Using Tumoroids Learn how our tumoroid models are advancing predictive modeling of immune-related adverse events in immunotherapy. Join us at Booth #928 to dive into these groundbreaking studies and see how Nilogen is pushing the boundaries of cancer research and therapy.  

We’re excited to continue sharing our innovations at SITC 2024! On 9th November 2024, join us to explore our cutting-edge research: 🔬 Advancing Cancer Therapy: High-Content Imaging for Precise Tumor Cell Killing Analysis in Patient-Derived Tumoroids Uncover how high-content imaging is enhancing our understanding of tumor cell killing with patient-derived tumoroids. 🔬 Enhancing T Cell Persistence in Adoptive Cell Therapy: Leveraging Tumoroid-Based ex-vivo Assays See how our tumoroid-based ex-vivo assays are improving preclinical evaluation of T cell persistence in adoptive cell therapies. 🔬 Assessing Immunotherapy Efficacy with the 3D-EXplore Platform: Focus on PD-1/PD-L1 Inhibitors in NSCLC Discover insights into the effectiveness of PD-1/PD-L1 inhibitors using Nilogen Oncosystems’ 3D-EXplore Platform for NSCLC tumors. 🔬 Predictive Modeling of Immune-Related Adverse Events Using Tumoroids Learn how our tumoroid models are advancing predictive modeling of immune-related adverse events in immunotherapy. Join us at Booth #928 to dive into these groundbreaking studies and see how Nilogen is pushing the boundaries of cancer research and therapy.  

We’re excited to continue sharing our innovations at SITC 2024! On 9th November 2024, join us to explore our cutting-edge research: 🔬 Advancing Cancer Therapy: High-Content Imaging for Precise Tumor Cell Killing Analysis in Patient-Derived Tumoroids Uncover how high-content imaging is enhancing our understanding of tumor cell killing with patient-derived tumoroids. 🔬 Enhancing T Cell Persistence in Adoptive Cell Therapy: Leveraging Tumoroid-Based ex-vivo Assays See how our tumoroid-based ex-vivo assays are improving preclinical evaluation of T cell persistence in adoptive cell therapies. 🔬 Assessing Immunotherapy Efficacy with the 3D-EXplore Platform: Focus on PD-1/PD-L1 Inhibitors in NSCLC Discover insights into the effectiveness of PD-1/PD-L1 inhibitors using Nilogen Oncosystems’ 3D-EXplore Platform for NSCLC tumors. 🔬 Predictive Modeling of Immune-Related Adverse Events Using Tumoroids Learn how our tumoroid models are advancing predictive modeling of immune-related adverse events in immunotherapy. Join us at Booth #928 to dive into these groundbreaking studies and see how Nilogen is pushing the boundaries of cancer research and therapy.  

We are excited to present our latest research at SITC 2024! Discover how Nilogen's ex-vivo 3D tumoroid platform is advancing CAR-T cell therapies for solid tumors by replicating the tumor microenvironment and extracellular matrix. This innovative system enables a comprehensive evaluation of CAR-T cell interactions and effectiveness, crucial for treatments like CD70-targeted therapies in renal cell carcinoma (RCC).   Our 3D-EXpress Tumoroid Platform also offers new insights into drug penetration and targeting, paving the way for more effective therapeutic strategies. Join us at Booth #928 to explore how our cutting-edge technology is revolutionizing cancer research and therapy development! Meet with Jared Ehrhart and learn more about our tumor model platforms!

We are excited to announce that we will be attending SITC 2024! Nilogen Oncosystems provides a unique 3D ex-vivo platform to study the mechanism of action, safety, and efficacy of your innovative therapeutics. We work with freshly procured patient tumor tissue which is minimally processed to preserve the extracellular matrix and immune milieu, closely mirroring the immune milieu in the patients. Meet our scientific and BD teams to discuss how we can support your pre-clinical and clinical drug development efforts using our unique 3D ex vivo platform.   To learn more, please stop by Booth #928.  We look forward to meeting you in Houston.

We are excited to announce that we will be attending SITC 2024! Nilogen Oncosystems provides a unique 3D ex-vivo platform to study the mechanism of action, safety, and efficacy of your innovative therapeutics. We work with freshly procured patient tumor tissue which is minimally processed to preserve the extracellular matrix and immune milieu, closely mirroring the immune milieu in the patients. Meet our scientific and BD teams to discuss how we can support your pre-clinical and clinical drug development efforts using our unique 3D ex vivo platform.   To learn more, please stop by Booth #928.  We look forward to meeting you in Houston.

We are excited to announce that we will be attending SITC 2024! Nilogen Oncosystems provides a unique 3D ex-vivo platform to study the mechanism of action, safety, and efficacy of your innovative therapeutics. We work with freshly procured patient tumor tissue which is minimally processed to preserve the extracellular matrix and immune milieu, closely mirroring the immune milieu in the patients. Meet our scientific and BD teams to discuss how we can support your pre-clinical and clinical drug development efforts using our unique 3D ex-vivo platform.   To learn more, please stop by Booth #928.  We look forward to meeting you in Houston.

Make this summer a season of discovery with Nilogen’s 3D ex vivo technology. Get rapid, actionable results and accelerate your journey from discovery to clinical application. For more information, visit www.nilogen.com or contact us at BD@nilogen.com.

Join us for a special LinkedIn Live interview on June 19 at 9 am PDT with Rikhia Chakraborty, Nilogen Oncosystems’ CSO. Explore the forefront of cancer technology with insights into our tumoroid platforms and discover how Nilogen is shaping the future of immuno-oncology, improving clinical outcome predictability. In conversation with Hersh Ashish Chaturvedi, VP with Strategic Partnerships, we will dive into the complexities of maintaining the tumor microenvironment and harnessing AI in biomedical research. Save the date and don't miss this exclusive opportunity to learn about the cutting-edge technologies in cancer research! #NilogenOncosystems #CancerResearch #Immunotherapy #BiomedicalInnovation #LinkedInLive #HealthcareTechnology #Tumoroidplatforms https://lnkd.in/gWN6btdp

We're thrilled to announce our participation at ASCO 2024! Visit us at Booth #35094 to discover why our advanced tumoroid platform is revolutionizing preclinical studies. 🔬 Why Tumoroids? Tumoroids offer a cutting-edge alternative to traditional 3D systems, providing more realistic models that closely mimic human cancer environments. This leap in technology enables more accurate and predictive analyses, setting a new standard for oncology research. 🤝 Meet Our Experts: Drop by to chat with our representatives William Coward, Jared Ehrhart, and Carlo Petruzziello. They're eager to share insights and discuss how Nilogen's innovative solutions can accelerate your research. Don't miss the opportunity to learn about the future of preclinical studies with us at ASCO 2024. See you there! #ASCO2024